Horizon Kinetics Medical ETF MEDX
37.88 USD -0.07 (-0.20%)
At closeNov 12, 2026, 4:00 PM EST
37.82 -0.06 -0.15%
After hours · Nov 12, 4:00 PM ET
37.88 Day range 37.88
31.71 52-week range 38.55
- YTD
- +14.08%
- 1 year
- +15.54%
News
globenewswire.com MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE FRANCHISE EXPANSION Austin , Texas, April 07, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE…
zacks.com Medical ETF (MEDX) Touches New 52-Week High MEDX hits a new 52-week high, as strength in patented pharma fuels fresh momentum.
accessnewswire.com Horizon Kinetics Holding Corporation Reports First Quarter Results Highlights for the Quarter ended March 31, 2025: Management and advisory fee revenue of $18.9 million for the quarter ended March 31, 2025, an increase of 58% over the first quarter of 2024 Net…
accessnewswire.com Horizon Kinetics Holding Corporation Reports Fourth Quarter and Annual Results Annual and Fourth Quarter 2024 Highlights: Revenues of $57.2 million for the year ended December 31, 2024, an increase of 21.0% Revenues of $19.2 million for the fourth quarter of 2024, an increase…
accesswire.com Horizon Kinetics Holding Corporation Announces Closing of Merger with Scott's Liquid Gold-Inc. Shares Will Continue Trading on a Pre-Reverse Split Basis NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Horizon Kinetics LLC ("Horizon Kinetics") announced the completion of the merger with Scott's Liquid Gold-Inc. ("SLGD"), which has been reincorporated in…
zacks.com ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
zacks.com ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
zacks.com Eli Lilly Beats on Q3 Earnings: ETFs to Buy Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
zacks.com Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs…
zacks.com Biotech ETFs in Focus on Covid Vaccines' Fall Rollout The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
zacks.com ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline,…
gurufocus.com 3 Value Plays the Oakmark International Small Cap Fund Is Buying The Oakmark Intl Small Cap (Trades, Portfolio) Fund recently disclosed its portfolio updates on its website for the fiscal quarter ended March 31. The company's fiscal year ends on Sept.